BAY-439 |
BAY-439 : Inhibitor of PLA2G5
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| PLA2G5 |
|
|
Inhibitor
up to 300 nM
Selectivity
In Vitro Selectivity Assessment
Potency Assay Off-Target:
Selectivity withing the target family: BAY-439 presents a selectivity window with 110-fold selectivi ...
In Vitro Selectivity Assessment
Potency Assay Off-Target:
BAY-439 was shown to be inactive on 4 enzymes (PLCβ3, PLCδ1, PLCγ1, PLCζ1) up to the highest concen ...
In Vitro Selectivity Assessment
Potency Assay Off-Target:
Eurofins Bayer Safety Screen (77 targets) at 10 µM: Closest off-targets: human SLC6A3 (82 % inhibiti ...
Potency Cellular
In Vitro
PLA2G5
Mode of Action: Inhibitor
Structure-Activity-Relationship data available? No
DOI Reference: 10.1021/acs.jmedchem.6c00488
In Vivo Validations
Rat
Dose: 0.5 mg/Kg IV, 3 mg/Kg PO
Route of delivery:
Intravenous, Oral
Plasma half life:
6.9 h IV, 6.0 h PO
Systemic clearance:
0.04 L/h/Kg
Bioavailability:
50%
Volume of Distribution at Steady-State:
0.2 L/Kg
DOI Reference: 10.1021/acs.jmedchem.6c00488
Negative Control Compounds
BAY-163
Notes: Biochemical assay: PLA2G5 human (IC50 > 25 µM), mouse/rat (IC50 > 20 µM), human PLA2G4A (IC50 >40 µM), PLA2G7 (IC50 > 40 µM), PLA2G2A (IC50 = 24.1 µM), PLA2G10 (IC50 = 14.3 µM); Nuvisan Phospholipase C panel: human PLCB3/PLCD1/PLCG1 / PLCZ1 (all IC50 >20 µM); Binding (SPR): human PLA2G5 (KD > 10 µM); Eurofins Bayer Safety Screen (77 targets) at 10 µM: Closest off-targets: human SLC6A3 (52 % inhibition), ADRA2C (54 % inhibition), Adenosine transporter (88 % inhibition) Kinase panel (378 kinases) at 10 μM: Closest off-target is DYRK1A (52 % inhibition)
SMILES:
CCNc1cc(C#Cc2ccc(cc2)OC2CCN(CC2)C(N(C)C)=O)ccn1
Chemical Information
Coming Soon...